Age-related macular degeneration is an eye disease that blurs the sharp, central vision needed for reading and many everyday tasks. It affects the macula, the part of the retina responsible for clear central vision, and is a leading cause of vision loss in older adults.
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
Semiconductor stocks surged as Intel, AMD, and POET hit fresh highs on AI infrastructure demand, while SemiLEDS jumped 17.96% after a Q3 turnaround. Intel posted stronger-than-expected Q1 earnings and upbeat Q2 guidance.
Axpaxli (OTX-TKI) met its primary endpoint in the SOL-1 Phase 3 trial, demonstrating superiority over aflibercept in preserving visual acuity in wet AMD patients at week 36. A single injection of the intravitreal hydrogel led to higher rescue-free rates and better fluid control, supporting potential for reduced treatment burden. Ocular Therapeutix plans to submit a New Drug Application to the FDA.
Immune checkpoint inhibitors are associated with a significantly lower risk of non-neovascular age-related macular degeneration, while sociodemographic disparities strongly influence diabetic retinopathy screening adherence, according to two separate ophthalmology studies.
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
Ocular Therapeutix announced positive topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI for wet age-related macular degeneration, meeting primary and durability endpoints with high statistical significance.
AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07700147 |
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration |
NOT_YET_RECRUITING | NA |
| NCT07424235 |
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort |
COMPLETED | |
| NCT07375901 |
the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration |
COMPLETED | NA |
| NCT07291960 |
Retinal Clinical Assessment With AI-derived Quantitative Information |
NOT_YET_RECRUITING | |
| NCT07269769 |
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD |
NOT_YET_RECRUITING | PHASE3 |
| NCT07216677 |
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases |
ACTIVE_NOT_RECRUITING | |
| NCT05547633 |
Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE) |
RECRUITING | |
| NCT05407636 |
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05056025 |
Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration. |
UNKNOWN | NA |
| NCT04796545 |
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration |
RECRUITING | NA |
